RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription
Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Wang, Jianjun [verfasserIn] Huang, Feng [verfasserIn] Shi, Yaxiang [verfasserIn] Zhang, Qinghui [verfasserIn] Xu, Song [verfasserIn] Yao, Yongliang [verfasserIn] Jiang, Runqiu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Gastric Cancer - Springer-Verlag, 2002, 24(2020), 1 vom: 04. Juli, Seite 85-102 |
|---|---|
| Übergeordnetes Werk: |
volume:24 ; year:2020 ; number:1 ; day:04 ; month:07 ; pages:85-102 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10120-020-01099-9 |
|---|
| Katalog-ID: |
SPR042607167 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR042607167 | ||
| 003 | DE-627 | ||
| 005 | 20210704064804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210108s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-020-01099-9 |2 doi | |
| 035 | |a (DE-627)SPR042607167 | ||
| 035 | |a (SPR)s10120-020-01099-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jianjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 | ||
| 520 | |a Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. | ||
| 650 | 4 | |a YAP1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hippo signaling |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunosuppression |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gastric cancer |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Huang, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yaxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qinghui |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Song |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yongliang |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Runqiu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 24(2020), 1 vom: 04. Juli, Seite 85-102 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2020 |g number:1 |g day:04 |g month:07 |g pages:85-102 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-020-01099-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2020 |e 1 |b 04 |c 07 |h 85-102 | ||
| author_variant |
j w jw f h fh y s ys q z qz s x sx y y yy r j rj |
|---|---|
| matchkey_str |
wangjianjunhuangfengshiyaxiangzhangqingh:2020----:p12n2pooeteainnynimnsprsinfuagsrcacry |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.1007/s10120-020-01099-9 doi (DE-627)SPR042607167 (SPR)s10120-020-01099-9-e DE-627 ger DE-627 rakwb eng Wang, Jianjun verfasserin aut RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. YAP1 (dpeaa)DE-He213 Hippo signaling (dpeaa)DE-He213 Immunosuppression (dpeaa)DE-He213 Gastric cancer (dpeaa)DE-He213 Huang, Feng verfasserin aut Shi, Yaxiang verfasserin aut Zhang, Qinghui verfasserin aut Xu, Song verfasserin aut Yao, Yongliang verfasserin aut Jiang, Runqiu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 24(2020), 1 vom: 04. Juli, Seite 85-102 (DE-627)SPR009286586 nnns volume:24 year:2020 number:1 day:04 month:07 pages:85-102 https://dx.doi.org/10.1007/s10120-020-01099-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 24 2020 1 04 07 85-102 |
| spelling |
10.1007/s10120-020-01099-9 doi (DE-627)SPR042607167 (SPR)s10120-020-01099-9-e DE-627 ger DE-627 rakwb eng Wang, Jianjun verfasserin aut RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. YAP1 (dpeaa)DE-He213 Hippo signaling (dpeaa)DE-He213 Immunosuppression (dpeaa)DE-He213 Gastric cancer (dpeaa)DE-He213 Huang, Feng verfasserin aut Shi, Yaxiang verfasserin aut Zhang, Qinghui verfasserin aut Xu, Song verfasserin aut Yao, Yongliang verfasserin aut Jiang, Runqiu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 24(2020), 1 vom: 04. Juli, Seite 85-102 (DE-627)SPR009286586 nnns volume:24 year:2020 number:1 day:04 month:07 pages:85-102 https://dx.doi.org/10.1007/s10120-020-01099-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 24 2020 1 04 07 85-102 |
| allfields_unstemmed |
10.1007/s10120-020-01099-9 doi (DE-627)SPR042607167 (SPR)s10120-020-01099-9-e DE-627 ger DE-627 rakwb eng Wang, Jianjun verfasserin aut RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. YAP1 (dpeaa)DE-He213 Hippo signaling (dpeaa)DE-He213 Immunosuppression (dpeaa)DE-He213 Gastric cancer (dpeaa)DE-He213 Huang, Feng verfasserin aut Shi, Yaxiang verfasserin aut Zhang, Qinghui verfasserin aut Xu, Song verfasserin aut Yao, Yongliang verfasserin aut Jiang, Runqiu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 24(2020), 1 vom: 04. Juli, Seite 85-102 (DE-627)SPR009286586 nnns volume:24 year:2020 number:1 day:04 month:07 pages:85-102 https://dx.doi.org/10.1007/s10120-020-01099-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 24 2020 1 04 07 85-102 |
| allfieldsGer |
10.1007/s10120-020-01099-9 doi (DE-627)SPR042607167 (SPR)s10120-020-01099-9-e DE-627 ger DE-627 rakwb eng Wang, Jianjun verfasserin aut RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. YAP1 (dpeaa)DE-He213 Hippo signaling (dpeaa)DE-He213 Immunosuppression (dpeaa)DE-He213 Gastric cancer (dpeaa)DE-He213 Huang, Feng verfasserin aut Shi, Yaxiang verfasserin aut Zhang, Qinghui verfasserin aut Xu, Song verfasserin aut Yao, Yongliang verfasserin aut Jiang, Runqiu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 24(2020), 1 vom: 04. Juli, Seite 85-102 (DE-627)SPR009286586 nnns volume:24 year:2020 number:1 day:04 month:07 pages:85-102 https://dx.doi.org/10.1007/s10120-020-01099-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 24 2020 1 04 07 85-102 |
| allfieldsSound |
10.1007/s10120-020-01099-9 doi (DE-627)SPR042607167 (SPR)s10120-020-01099-9-e DE-627 ger DE-627 rakwb eng Wang, Jianjun verfasserin aut RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. YAP1 (dpeaa)DE-He213 Hippo signaling (dpeaa)DE-He213 Immunosuppression (dpeaa)DE-He213 Gastric cancer (dpeaa)DE-He213 Huang, Feng verfasserin aut Shi, Yaxiang verfasserin aut Zhang, Qinghui verfasserin aut Xu, Song verfasserin aut Yao, Yongliang verfasserin aut Jiang, Runqiu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 24(2020), 1 vom: 04. Juli, Seite 85-102 (DE-627)SPR009286586 nnns volume:24 year:2020 number:1 day:04 month:07 pages:85-102 https://dx.doi.org/10.1007/s10120-020-01099-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 24 2020 1 04 07 85-102 |
| language |
English |
| source |
Enthalten in Gastric Cancer 24(2020), 1 vom: 04. Juli, Seite 85-102 volume:24 year:2020 number:1 day:04 month:07 pages:85-102 |
| sourceStr |
Enthalten in Gastric Cancer 24(2020), 1 vom: 04. Juli, Seite 85-102 volume:24 year:2020 number:1 day:04 month:07 pages:85-102 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
YAP1 Hippo signaling Immunosuppression Gastric cancer |
| isfreeaccess_bool |
false |
| container_title |
Gastric Cancer |
| authorswithroles_txt_mv |
Wang, Jianjun @@aut@@ Huang, Feng @@aut@@ Shi, Yaxiang @@aut@@ Zhang, Qinghui @@aut@@ Xu, Song @@aut@@ Yao, Yongliang @@aut@@ Jiang, Runqiu @@aut@@ |
| publishDateDaySort_date |
2020-07-04T00:00:00Z |
| hierarchy_top_id |
SPR009286586 |
| id |
SPR042607167 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR042607167</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210704064804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210108s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-020-01099-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR042607167</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-020-01099-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wang, Jianjun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">YAP1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hippo signaling</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppression</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Feng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shi, Yaxiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Qinghui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Song</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yao, Yongliang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Runqiu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">24(2020), 1 vom: 04. Juli, Seite 85-102</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">day:04</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:85-102</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-020-01099-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="b">04</subfield><subfield code="c">07</subfield><subfield code="h">85-102</subfield></datafield></record></collection>
|
| author |
Wang, Jianjun |
| spellingShingle |
Wang, Jianjun misc YAP1 misc Hippo signaling misc Immunosuppression misc Gastric cancer RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription |
| authorStr |
Wang, Jianjun |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009286586 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription YAP1 (dpeaa)DE-He213 Hippo signaling (dpeaa)DE-He213 Immunosuppression (dpeaa)DE-He213 Gastric cancer (dpeaa)DE-He213 |
| topic |
misc YAP1 misc Hippo signaling misc Immunosuppression misc Gastric cancer |
| topic_unstemmed |
misc YAP1 misc Hippo signaling misc Immunosuppression misc Gastric cancer |
| topic_browse |
misc YAP1 misc Hippo signaling misc Immunosuppression misc Gastric cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Gastric Cancer |
| hierarchy_parent_id |
SPR009286586 |
| hierarchy_top_title |
Gastric Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR009286586 |
| title |
RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription |
| ctrlnum |
(DE-627)SPR042607167 (SPR)s10120-020-01099-9-e |
| title_full |
RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription |
| author_sort |
Wang, Jianjun |
| journal |
Gastric Cancer |
| journalStr |
Gastric Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
85 |
| author_browse |
Wang, Jianjun Huang, Feng Shi, Yaxiang Zhang, Qinghui Xu, Song Yao, Yongliang Jiang, Runqiu |
| container_volume |
24 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Wang, Jianjun |
| doi_str_mv |
10.1007/s10120-020-01099-9 |
| author2-role |
verfasserin |
| title_sort |
rp11-323n12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing yap1 transcription |
| title_auth |
RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription |
| abstract |
Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 |
| abstractGer |
Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 |
| abstract_unstemmed |
Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics. © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
1 |
| title_short |
RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription |
| url |
https://dx.doi.org/10.1007/s10120-020-01099-9 |
| remote_bool |
true |
| author2 |
Huang, Feng Shi, Yaxiang Zhang, Qinghui Xu, Song Yao, Yongliang Jiang, Runqiu |
| author2Str |
Huang, Feng Shi, Yaxiang Zhang, Qinghui Xu, Song Yao, Yongliang Jiang, Runqiu |
| ppnlink |
SPR009286586 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10120-020-01099-9 |
| up_date |
2024-07-03T13:49:43.983Z |
| _version_ |
1803566012419801088 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR042607167</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210704064804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210108s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-020-01099-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR042607167</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-020-01099-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wang, Jianjun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background YAP1 is a core protein of the Hippo signaling pathway and is associated with malignancy and immunosuppression. In the present study, we discovered a novel lncRNA, RP11-323N12.5, with tumor promotion and immunosuppression activities through enhancing transcription of YAP1. Methods RP11-323N12.5 was identified using GEPIA. Its expression levels and their relationship with clinical features were investigated using clinical samples. The regulation of YAP1 transcription by RP11-323N12.5 was investigated in both GC and T cells, the tumor and immunosuppression promotion roles of RP11-323N12.5 were explored in vitro and in vivo. Results RP11-323N12.5 was the most up-regulated lncRNA in human GC, based on data from the TCGA database. Its transcription was significantly positively correlated with YAP1 transcription, YAP1 downstream gene expression which contribute to tumor growth and immunosuppression. RP11-323N12.5 promoted YAP1 transcription by binding to c-MYC in the YAP1 promoter region. Meanwhile, transcription of RP11-323N12.5 was also regulated by YAP1/TAZ/TEADs activation in GC cells. RP11-323N12.5 had tumor- and immnosuppression-promoting effects by enhancing YAP1 downstream genes in GC cells. Excessive RP11-323N12.5 was also observed in tumor-infiltrating leukocytes (TILs), which may be exosome-derived and also be related to enhanced Treg differentiation as a result YAP1 up-regulation. Moreover, RP11-323N12.5 promoted tumor growth and immunosuppression via YAP1 up-regulation in vivo. Conclusions RP11-323N12.5 was the most up-regulated lncRNA in human GC and it promoted YAP1 transcription by binding to c-MYC within the YAP1 promoter in both GC and T cells. RP11-323N12.5 is an ideal therapeutic target in human GC due to its tumor-promoting and immunosuppression characteristics.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">YAP1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hippo signaling</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppression</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Feng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shi, Yaxiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Qinghui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Song</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yao, Yongliang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Runqiu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">24(2020), 1 vom: 04. Juli, Seite 85-102</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">day:04</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:85-102</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-020-01099-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="b">04</subfield><subfield code="c">07</subfield><subfield code="h">85-102</subfield></datafield></record></collection>
|
| score |
7.4009047 |